InterDigital, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that InterDigital, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $75.33M | Feb 21, 2019 |
| FY2018 | Sep 30, 2018 | $75.08M | Feb 21, 2019 |
| FY2018 | Jun 30, 2018 | $69.56M | Feb 21, 2019 |
| FY2018 | Mar 31, 2018 | $87.44M | Feb 21, 2019 |
| FY2018 | Dec 31, 2017 | $205.30M | Feb 21, 2019 |
| FY2018 | Sep 30, 2017 | $97.33M | Feb 21, 2019 |
| FY2018 | Jun 30, 2017 | $135.78M | Feb 21, 2019 |
| FY2018 | Mar 31, 2017 | $94.53M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $273.87M | Feb 22, 2018 |
| FY2017 | Sep 30, 2016 | $208.31M | Feb 22, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $834.02M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $868.52M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $549.59M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $457.79M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $425.41M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $90.79M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $87.49M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $104.50M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $76.21M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $102.16M | Feb 18, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Dec 31, 2010 | $394.55M | Feb 28, 2011 |
| FY2010 | Dec 31, 2009 | $297.40M | Feb 28, 2011 |
| FY2010 | Dec 31, 2008 | $228.47M | Feb 28, 2011 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $406.64M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $358.61M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $214.07M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $93.69M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $55.30M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | ($1.35M) | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $23.78M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $22.25M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $116.0K | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $13.75M | Feb 18, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $460.85M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $439.51M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $221.62M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $150.52M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $71.21M | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | $3.14M | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | $15.43M | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | $31.92M | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | $4.68M | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | $25.30M | Feb 18, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $185.20M | Feb 15, 2023 |
| FY2022 | Dec 31, 2021 | $200.50M | Feb 15, 2023 |
| FY2022 | Dec 31, 2020 | $204.40M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $74.86M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $69.70M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $75.72M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $73.12M | Feb 21, 2019 |
| FY2017 | Dec 31, 2015 | $72.70M | Feb 22, 2018 |
| FY2016 | Dec 31, 2014 | $75.30M | Feb 23, 2017 |
| FY2015 | Dec 31, 2013 | $64.73M | Feb 18, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $61.22M | Feb 17, 2022 |
| FY2021 | Dec 31, 2020 | $49.00M | Feb 17, 2022 |
| FY2021 | Dec 31, 2019 | $51.29M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $51.03M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $53.07M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $52.07M | Feb 21, 2019 |
| FY2017 | Dec 31, 2015 | $39.78M | Feb 22, 2018 |
| FY2016 | Dec 31, 2014 | $37.75M | Feb 23, 2017 |
| FY2015 | Dec 31, 2013 | $31.30M | Feb 18, 2016 |
| FY2013 | Dec 31, 2012 | $37.35M | Feb 19, 2015 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $544.45M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $271.53M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $213.73M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $286.04M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $130.39M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $163.47M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $89.43M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $146.79M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $315.80M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $434.16M | Feb 21, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.89M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $5.85M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $4.27M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $3.16M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $2.51M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $11.79M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $4.51M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $2.58M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $2.07M | Feb 20, 2020 |
| FY2018 | Dec 31, 2016 | $5.88M | Feb 21, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.06B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.84B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.77B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $1.90B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.63B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.62B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.61B | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $1.63B | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $1.85B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $1.73B | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $963.17M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $978.31M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.19B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $1.17B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $875.24M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $819.71M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $825.80M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $688.55M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $981.27M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $973.49M | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.10B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $857.22M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $581.55M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $724.90M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $745.24M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $773.37M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $761.56M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $936.73M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $855.27M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $739.71M | Feb 22, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.07M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $22.42M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $22.42M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $22.42M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $22.42M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $22.42M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $22.42M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $22.42M | Feb 18, 2021 |
| FY2019 | Dec 31, 2017 | $16.03M | Feb 20, 2020 |
| FY2017 | Dec 31, 2016 | $16.20M | Feb 22, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.78B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.46B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $1.49B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.44B | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.41B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.41B | Feb 18, 2021 |
| FY2017 | Jan 1, 2018 | ($1.41B) | Feb 22, 2018 |
| FY2017 | Dec 31, 2017 | ($1.25B) | Feb 22, 2018 |
| FY2010 | Dec 31, 2010 | $395.80M | Mar 28, 2011 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $738.96M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $527.36M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $437.08M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $693.48M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $706.28M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $473.47M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $745.49M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | $475.06M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | $433.01M | Feb 21, 2019 |
| FY2018 | Dec 31, 2016 | $404.07M | Feb 21, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2014 | $217.84M | Feb 19, 2015 |
| FY2013 | Dec 31, 2013 | $208.81M | Feb 19, 2015 |
| FY2013 | Dec 31, 2012 | $200.39M | Feb 24, 2014 |
| FY2012 | Dec 31, 2011 | $192.71M | Feb 26, 2013 |
| FY2011 | Dec 31, 2010 | $468.0K | Feb 27, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 15 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 14 | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 12 | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 7 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 15, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 18, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 18, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.69M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 25.68M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | 25.58M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | 29.67M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 30.69M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 30.82M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | 30.70M | Feb 18, 2021 |
| FY2019 | Dec 31, 2018 | 33.53M | Feb 20, 2020 |
| FY2018 | Dec 31, 2017 | 34.62M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 34.30M | Feb 22, 2018 |